Menu Search
Equities

Wockhardt Ltd

WOCKPHARMA:NSI

Wockhardt Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,233.40
  • Today's Change67.40 / 5.78%
  • Shares traded573.50k
  • 1 Year change+269.95%
  • Beta1.9934
Data delayed at least 15 minutes, as of Nov 22 2024 10:22 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Wockhardt Ltd grew revenues 5.55% from 26.51bn to 27.98bn while net income improved from a loss of 5.59bn to a smaller loss of 4.63bn.
Gross margin59.10%
Net profit margin-10.00%
Operating margin0.10%
Return on assets-3.93%
Return on equity-8.83%
Return on investment-6.33%
More ▼

Cash flow in INRView more

In 2024, Wockhardt Ltd increased its cash reserves by 461.11%, or 4.15bn. Cash Flow from Financing totalled 3.34bn or 11.94% of revenues. In addition the company generated 2.19bn in cash from operations while cash used for investing totalled 1.37bn.
Cash flow per share-4.98
Price/Cash flow per share--
Book value per share221.32
Tangible book value per share61.73
More ▼

Balance sheet in INRView more

Wockhardt Ltd has a Debt to Total Capital ratio of 38.69%, a higher figure than the previous year's 37.34%.
Current ratio0.8437
Quick ratio0.5677
Total debt/total equity0.6901
Total debt/total capital0.3869
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.